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Abstract
Objective: In current clinical practice, optimal treatment of inflammatory bowel disease (IBD) aims at the induction and
maintenance of clinical remission. Clinical remission is apparent when laboratory markers of inflammation are normal and
clinical symptoms are absent. However, sub-clinical inflammation can still be present. A detailed analysis of the immune
status during this inactive state of disease may provide a useful tool to categorize patients with clinical remission into
subsets with variable states of immune activation.
Design: By using Affymetrix GeneChips, we analysed RNA gene expression profiles of peripheral blood leukocytes from
pediatric IBD patients in clinical remission and controls. We performed (un)supervised clustering analysis of IBD-associated
genes and applied IngenuityH pathway software to identify specific molecular profiles between patients.
Results: Pediatric IBD patients with disease in clinical remission display heterogeneously distributed gene expression
profiles that are significantly distinct from controls. We identified three clusters of IBD patients, each displaying specific
expression profiles of IBD-associated genes.
Conclusion: The expression of immune- and IBD-associated genes in peripheral blood leukocytes from pediatric IBD
patients in clinical remission was different from healthy controls, indicating that sub-clinical immune mechanisms are still
active during remission. As such, RNA profiling of peripheral blood may allow for non-invasive patient subclassification and
new perspectives in treatment regimes of IBD patients in the future.
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Introduction
Inflammatory bowel disease (IBD) is known as a chronic
inflammatory disease of the intestine. Although multiple treatment
options have been used to control inflammation, to date no
curative interventions have been described. Therefore, the major
aim of treatment is the induction and preservation of clinical
remission. Furthermore, differences in phenotype, medication
responsiveness and associated genetic polymorphisms, illustrate
that IBD patients represent a heterogeneous group that may need
a novel classification beyond that of Crohn’s disease (CD) and
ulcerative colitis (UC). Specifically, genotype, RNA expression,
demographic parameters and disease location may help to
discriminate subsets within this patient population. Of note, 15%
of all IBD cases have disease onset during childhood. [1] Given the
distinct disease phenotype and associated pathological changes in
children compared to adults, pediatric disease onset can be seen as
a specific subset of IBD. [1,2,3,4].
Clinical remission in pediatric IBD is defined as the absence of
symptoms of disease, that is expressed as the pediatric Crohn’s
disease activity index (PCDAI) or pediatric ulcerative colitis
activity index (PUCAI). In both PCDAI and PUCAI, a score ,10
defines remission and scores from 10–30 represent mild active
disease. [5,6] The PCDAI describes the overall disease activity and
includes laboratory findings, growth and overall wellbeing,
whereas the PUCAI only involves clinical signs and symptoms.
Although endoscopic disease activity is not part of either PCDAI
or PUCAI, the latter has been found to correlate well with
colonoscopic appearance in active disease. [6] Correlation of
endoscopy and clinical indices during remission is less clear and
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thus inflammatory processes can be present on a macroscopic as
well as a microscopic level in patients who experience no
symptoms of active disease. [7] Specifically, subclinical immune
activation might still be present despite the absence of clinical
symptoms. [8,9,10] A detailed analysis of the immune status of
patients during remission or mild active disease scores may provide
an approach to identify patient subclassifications with subclinical
immune activation.
Laboratory markers of inflammation (e.g. CRP and ESR) and
fecal calprotectine are associated with (imminent) disease exacer-
bation. [11,12] Moreover, severity of disease may be predicted
based upon a panel of genetic polymorphisms. [13] However, the
usefulness of these parameters for individual patients seems
limited. [14] As such, in depth analysis of systemic expression
profiles of specific genes involved in the pathogenesis of IBD may
help to subclassify IBD patients and may lead to new perspectives
in treatment regimes of IBD patients.
To assess the immune status during clinical remission, we
analysed gene expression profiles of peripheral blood leukocytes
(PBL) obtained from pediatric IBD patients with inactive to mildly
active disease as well as control individuals. By using unsupervised
clustering analysis, supervised analysis of IBD-associated gene
expression as well as IngenuityH pathway analysis (Ingenuity), we
detected notable differences in gene expression profiles when
comparing pediatric IBD patients with healthy controls.
These data indicate that the immune status of pediatric IBD
patients during clinical remission is not comparable to that of
healthy controls and extents to the peripheral blood compartment.
Materials and Methods
Patients
A cohort of 45 pediatric IBD patients in clinical remission
(24 CD patients and 21 UC patients) with a median age of 16.0
years (IQR 15.0–17.0) were included in this study, as well as 13
controls (Table S1). The control group consisted of orthopaedic
patients and did not suffer from inflammatory or intestinal disease
at the time of inclusion. This group was recruited during a
scheduled control at the hospital.
All patients had received a diagnosis of CD or UC by standard
diagnostic work-up according to the Porto criteria. [15] Clinical
Disease activity was assessed in the outpatient clinic using the
PCDAI and PUCAI indexes for CD and UC, respectively. [5,6].
None of the IBD patients had overt clinical disease activity upon
inclusion. When scoring for clinical remission using the PCDAI
Figure 1. Gene expression profiles of quiescent pediatric IBD patients. Global gene expression profiles of peripheral blood leukocytes were
analysed using principal components analysis (PCA). Samples with higher similarity between gene expression profiles cluster more strongly together
in the PCA space. Crohn’s disease (red) and ulcerative colitis (green) patients with quiescent disease are not different from each other and form a
heterogeneous cluster that is distinct from controls (blue).
doi:10.1371/journal.pone.0079549.g001
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and PUCAI, a majority (71%) had a clinical remission score ,10.
A minor proportion had a mild-active phenotype, scoring 10–30.
None of the patients had a score .30 reflecting active disease.
Patients received different medication regimes. The majority of
CD patients were given azathioprine, whereas most UC patients
were given mesalazine. Four patients received prednisolone. Each
patient was followed for 18 months for clinical characteristics from
the time the blood sample was obtained. Approval for this study
was obtained by the Medical Ethics Committee Erasmus MC,
Rotterdam, The Netherlands (METC 2007-335). All patients and
parents provided their written informed consent to participate in
this study.
Isolation and Quality Control of RNA
Venous blood (2ml) was collected in PAXgene tubes (Pre-
AnalytiX) and stored at –20uC until RNA extraction. Total
cellular RNA was extracted using the PAXgene blood RNA kit
(Qiagen) according to the manufacturer’s protocol. RNA levels,
quality and purity were assessed with the RNA 6000 Nano assay
on the Agilent 2100 Bioanalyzer (Agilent). The samples did not
show RNA degradation or contamination with DNA.
Gene Expression Profiling and Quality Control
Samples were analysed by Affymetrix GeneChip Human
genome U133 plus 2.0 arrays as described earlier. The GeneChip
contains 54,675 probe sets, representing approximately 39,000
genes. Biotinylated antisense cRNA was prepared from 5 mg of
total RNA using the one-cycle labelling kit (Affymetrix, Santa
Clara, CA). cRNA was hybridized on the GeneChip human
genome U133 plus 2.0 array (Affymetrix)45uC for 16–18 hours.
Staining, washing and scanning procedures were carried out
according to the manufacturer’s protocol (Affymetrix). All
GeneChips were visually inspected for irregularities. The R
package AffyQC-report was used for quality control and indicated
high quality and overall comparability of all samples.
The dataset is located at NIH, gene expression omnibus (GEO).
Accession number of repository for expression microarray data:
GSE33943.
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE33943.
Data Normalization, Statistical Analysis, and
(Un)supervised Analyses
Data were normalized as previously described. [16] In short,
raw intensity values of all samples were normalized by background
correction and quantile normalization using the version 6.4
Robust Multichip Analysis (Partek). To visualize the correlation
between the samples, principal component analysis (PCA) was
used. The normalized data file was transposed and imported into
OmniViz version 6.0.3 (Biowisdom) for further analysis.
Unsupervised and supervised cluster analyses were performed in
Omniviz using Pearson’s correlation in the Correlation View. We
used cut-off values for significantly expressed genes with a fold
change of 1.5 and a false discovery rate (FDR) of ,0.05.
Supervised analysis was based on Significance Analysis of
Microarrays (SAM). [17] Functional annotation of the SAM
results were performed by using Ingenuity.
Figure 2. Correlation plot of quiescent IBD patients involving 2957 probe sets. Pair-wise correlations between the samples are depicted in
a Pearson’s correlation plot. The colours of the cells relate to Pearson’s correlation coefficient values, with deeper colours indicating higher positive
(red) or negative (blue) correlations. This Pearson’s correlation plot revealed three distinct groups (A, B, C). Controls are annotated to group A.
doi:10.1371/journal.pone.0079549.g002
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Group analyses were performed using Pearson’s Rank correla-
tion, student’s T-test, Kruskall - Wallis and Chi-square test when
appropriate. P values ,0.05 were considered significant.
Results
Gene Expression Profiles of Pediatric IBD Patients are
Heterogeneously Distributed and Independent of Type
of Disease
Gene expression profiles of PBL from both IBD patients and
controls were analysed by using PCA. This type of analysis
visualizes clustering of those samples that display comparable
expression profiles (Figure 1). In our cohort, control samples
appear in a homogeneous cluster (blue) whereas both CD (red) and
UC (green) patients clustered together based on overall gene
expression profiles. In the PCA some IBD patients were in close
vicinity of the controls. However, the majority of the IBD patients
appeared at a location that was distinct from the cluster of
controls.
As such, IBD patients in clinical remission or mildly active
disease are not comparable to healthy individuals based on overall
gene expression profiles. Moreover, as we did not observe separate
clusters for CD and UC patients, classical sub-categorization into
type of disease may not apply for patients in clinical remission.
IBD Patients can be Subdivided into Three Groups Based
on a 3-fold Difference in Gene Expression Level
Next, we determined whether the heterogeneous cluster of IBD
patients could be subclassified into newly defined subgroups,
according to unsupervised ordering of their gene expression
profiles. Therefore, we generated a Pearson’s correlation plot that
included probe sets with a 3-fold difference in gene expression
level relative to the geometric mean of expression, reflecting up- or
down-regulation. In total, 2957 records met these criteria and
correlation between the samples was analysed on the basis of
similarities in gene expression profiles. Samples that show positive
correlation in gene expression profiling are indicated in red,
whereas negative correlation is illustrated in blue. This Pearson’s
correlation plot revealed three distinct groups, which we annotated
as group A, B and C. All control samples were located in group A,
whereas both CD and UC patients were heterogeneously
distributed over all three groups (Figure 2).
To assess whether there may have been underlying (clinical)
parameters that influenced the RNA profiling, we compared the
disease characteristics for each group in more detail (Table 1). We
Table 1. Group characteristics.
Group A B C
# % # % # % p-value
N 18 12 15
Female 7 38.9 6 50.0 13 86.7 0.02
CD 10 55.6 6 50.0 8 53.3 0.90
Remission 16 88.9 6 50.0 10 66.7 0.06
(PCDAI/PUCAI ,10)
Medication # % # % # %
Azathioprine 9 50.0 7 58.3 4 26.7
Inflixmab 0 0 1 8.3 1 6.7
Prednisolone 1 5.6 1 8.3 2 13.3
Mesalazine 9 50.0 4 33.3 5 33.3
Methotrexate 1 5.6 1 8.3 3 20.0
Sulfasalazine 1 5.6 0 0 2 13.3
None 1 5.6 0 0 1 6.7
Median IQR Median IQR Median IQR
PCDAI/PUCAI 0 0–5 10 0–20 1 0–16.25 0.23
ESR (mm/h) 6 3.75–15.25 5 3–13.25 14 8.75–24.25 0.04
CRP (mmol/l) 1 1–3.75 1 1–3 2 1–6,5 0.52
Age (y) 16,5 15–17 15 14.25–16 16 15–16 0.05
Age onset (y) 12 11–14 11 6.25–15 14 11–15 0.24
Median IQR Median IQR Median IQR
B-cells (CD19+) (%) 1.15 0.57–2.78 1.16 0.67–2.25 1.44 0.10–3.32 0.55
Th-cells (CD3+CD4+) (%) 11.32 9.91–13.54 6.77 4.61–11.55 7.53 3.71–8.88 0.04
Tc-cells (CD3+CD8+) (%) 4.58 4.03–8.08 3.39 2.35–5.05 4.01 1.42–4.62 0.23
Granulocytes (%) 48.82 28.02–57.67 23.68 13.71–33.62 57.08 50.63–64.88 0.01
Monocytes (%) 4.65 2.81–10.45 2.77 1.19–5.02 8.02 5.70–11.59 0.01
doi:10.1371/journal.pone.0079549.t001
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found no significant difference in clinical parameters (PCDAI or
PUCAI scores, CRP, medication, disease type, behaviour and
location) between the groups. However, patients in group C
displayed a slightly higher ESR (p,0.05). Patients of group A were
slightly older compared to the patients of group B (p,0.05), and
patients of group C consisted mainly of females (87%) (Table 1).
The records that were included for the Pearson correlation plot
were located on multiple chromosomes. Only a small percentage
of these records (3.5% of all included records genes, 5% in group
C) were located on the X or Y chromosome (data not shown).
Measurement by flow cytometry of immune cells in peripheral
blood showed increased percentages of monocytes and granulo-
cytes compared in group C (p,0.001). Medication regimes were
comparable between the three groups. (Table 1).
By using unsupervised clustering analysis, we show that IBD
patients with clinically inactive disease can be subclassified into
three groups with distinct gene expression profiles. CD and UC
patients were present in equal percentages within each group and
14 IBD patients clustered together with controls.
Three Clusters of IBD Patients in Remission Each Display
Specific Immunological Expression Profiles
In order to investigate whether the IBD patients of the three
subgroups showed differences in IBD-associated immune func-
tions, we analysed the expression of IBD-associated genes (Table
S2) in the three separate clusters in a supervised manner. For this
analysis we excluded the controls from group A. First, we
determined for each group which probe sets showed .1.5 fold
higher or lower expression compared to controls. Next, we
determined which of these probes sets were significantly different
between IBD patients and controls by SAM analysis. Although the
majority of IBD patients are in clinical remission or mild active
disease, the expression of various IBD-associated genes were found
to differ significantly from controls. IBD patients in group A
displayed a significantly different expression for 31 IBD-associated
probe sets, whereas group B and C contained 151 and 161 probe
sets, respectively (Table S3).
Next, we compared the expression levels of several immuno-
logical probe sets within the three groups of IBD patients and
controls. We found that for group A, only two immunological
probe sets were differentially expressed compared to controls
and the two other groups. Group B displayed specific gene
expression for 75 probe sets, whereas in group C 26 probe sets
were distinct from controls as well as from the two other groups
(Table S4).
These results indicate that although the clinical phenotype of
the IBD patients and controls is comparable, expression levels of
IBD-associated genes are significantly different between the IBD
patients and controls. Furthermore, by performing supervised
analysis between the three groups, as defined in Figure 2, we show
that the groups were at least in part divided on the basis of gene
expression profiles of IBD-associated immune genes.
Ingenuity Pathway Analysis Reveals Group-specific
Involvement of Immunological Pathways
In order to investigate the possible interaction of the differen-
tially expressed immunological genes, we analysed for each patient
group which immunological pathways were associated with these
genes by using IngenuityH. The pathways within groups A, B and
C that were distinct from controls involved immunological
pathways at all levels of the immune cascade, ranging from
pattern recognition to adaptive immune cell activation (Table 2).
In all groups, genes of the glucocorticoid receptor signaling
pathway showed differential expression compared to controls,
while for example the IL-4 signaling pathway was only signifi-
cantly modulated in groups B and C. By performing Ingenuity
pathway analysis, we determined which pathways derived from
Table S4 were most distinctive for each group individually
(Table 3).
This in depth analysis indicated that in IBD patients with
clinical remission of mildly active disease, active immune processes
were still differentially modulated in comparison to the healthy
controls. These active processes were shown to participate in
distinct, well-known immune-related pathways.
Supervised Analysis Indicated Differences in Gene
Expression Profiles of IBD-associated Genes
Next, we investigated whether the active immune processes
found during clinical remission could predict exacerbation or
clinical inflammation. We determined gene expression profiles of
IBD-associated genes in relation to exacerbations during a one and
a half year follow-up from inclusion. Within this time frame, 61%
of the CD patients and 76% of the UC patients encountered one
or more exacerbations. We did not find differences in the
occurrence of exacerbations between groups A, B and C (data
not shown).
Supervised analysis of the patients that had one or more
exacerbations indicated that multiple IBD-associated genes were
differentially expressed in the remission phase, specifically in CD
patients that developed an exacerbation compared to CD patients
with sustained remission (Table S5). We did not detect any
difference in IBD-associated gene expression when we performed
a similar analysis for UC patients (data not shown). Furthermore,
only three IBD-related genes were differentially expressed between
CD and UC patients, whereas seventeen IBD-related genes were
differentially expressed in CD patients with ileitis or ileocolitis
(74%) at the time of diagnosis compared to CD patients without
ileal involvement (Table S5).
Discussion
Bioinformatics-based integration of molecular and clinical
information has proven to be crucial for the discovery of new
disease pathways relevant to identify subclasses of various diseases.
[16] Using gene expression arrays in IBD, multiple genes have
been discovered which are associated with activity of disease,
phenotype (e.g. CD and UC) and age of onset of IBD.
[18,19,20,21,22,23] However, most of these studies were per-
formed using supervised analysis in order to find associated genes
for CD compared to UC or for disease activity. This study is, to
our knowledge, the first that includes pediatric IBD patients in
clinical remission or mild active disease and encompasses
unsupervised analyses of gene expression profiles in peripheral
blood. By using this approach, we have now revealed substantial
differences between non-symptomatic IBD patients and controls
and have catalogued and analysed genes that were differentially
expressed between IBD patients and healthy persons.
Given the ethical limitations of performing colonoscopy with
biopsies in pediatric IBD patients during clinical remission, we
decided to focus on expression arrays of PBL. Numerous studies
have shown potential immunological differences in peripheral
derived immune cells from IBD patients in the active stages of the
disease. [21,24,25,26,27,28] Using gene expression arrays of PBL,
we have shown that the majority of pediatric IBD patients
experiencing clinical remission have gene expression profiles that
are diverse and distinct from controls (Figure 1). Interestingly, CD
and UC patients did not form separate clusters within the PCA,
Subclassification of Pediatric IBD in Remission
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suggesting immunological similarities between these two subsets in
this inactive phase of disease. Over the last years multiple SNPs
have been found in active IBD patients that are specific for CD
and UC. Interestingly, overlap for some of these SNPs has been
established between CD and UC. [29,30].
By using unsupervised analysis on the genes, we have
subclassified pediatric IBD patients in remission or mild active
disease into three distinct groups (Figure 2). Although non-
immune genes were overrepresented in these three groups, we also
observed significant differences in immunological gene expression
profiles between controls as well as between groups (Tables S3 and
S4). The majority of these genes were upregulated when compared
to controls, suggesting activation of associated pathways. We
performed Ingenuity pathway analysis in order to investigate
which pathways were affected by the various differentially
expressed genes in the IBD groups and controls. By this method
we could identify the associated pathways (Tables 2 and 3) for each
gene. Most importantly, genes involved in the glucocorticoid
receptor signaling pathway showed enhanced expression in group
B and C. As these two groups were most distinct from controls in
the Pearson’s correlation plot (Figure 2), we conclude that this
pathway plays an important role in the distinction between
controls and asymptomatic IBD patients. Continuous activation of
the glucocorticoid receptor signaling pathway could indicate that
these patients request a more robust anti-inflammatory medication
regime in order to preserve remission.
Although all groups had comparable PCDAI/PUCAI scores,
patients of group C had a higher ESR and increased amounts of
Table 2. Top canonical pathways Group A/B/C vs Control.
Name p-value ratio
A vs Control Glucocorticoid Receptor Signaling 1.01e-23 16/280 (0.057)
Role of NFAT in Regulation of the Immune Response 1.75e-16 11/194 (0.057)
Systemic Lupus Erythematosus Signaling 1.11e-15 10/150 (0.067)
iCOS-iCOSL Signaling in T Helper Cells 6.51e-13 8/115 (0.07)
T Cell Receptor Signaling 7.77e-13 8/110 (0.073)
B vs Control Glucocorticoid Receptor Signaling 9.26e-92 61/280 (0.218)
Estrogen Receptor Signaling 1.46e-42 29/121 (0.24)
Colorectal Cancer Metastasis Signaling 3.56e-22 22/247 (0.089)
IL-4 Signaling 2.63e-21 15/72 (0.208)
B Cell Receptor Signaling 1.97e-20 18/155 (0.116)
C vs Control Glucocorticoid Receptor Signaling 5.66e-72 52/280 (0.186)
IL-4 Signaling 2.65e-19 14/72 (0.194)
Dendritic Cell Maturation 1.60e-18 17/173 (0.098)
RAR Activation 1.26e-17 17/178 (0.096)
Systemic Lupus Erythematosus Signaling 1.41e-16 15/150 (0.1)
doi:10.1371/journal.pone.0079549.t002
Table 3. Top canonical pathways Group A/B/C vs Group and Controls.
Name p-value ratio
A vs B,C and controls Role of PKR in Interferon Induction and Antiviral Response 4.05e-03 1/46 (0.022)
Fcg Receptor-mediated Phagocytosis in Macrophages and Monocytes 9.21e-03 1/104 (0.01)
Systemic Lupus Erythematosus Signaling 1.24e-02 1/150 (0.007)
Dendritic Cell Maturation 1.44e-02 1/173 (0.006)
Role of NFAT in Regulation of the Immune Response 1.59e-02 1/194 (0.005)
B vs A,C and controls Glucocorticoid Receptor Signaling 1.89e-51 34/280 (0.121)
Estrogen Receptor Signaling 9.51e-28 18/121 (0.149)
Colorectal Cancer Metastasis Signaling 4.28e-14 13/247 (0.053)
HMGB1 Signaling 8.82e-14 10/98 (0.102)
LPS-stimulated MAPK Signaling 3.98e-13 9/80 (0.112)
C vs A,B and controls Glucocorticoid Receptor Signaling 5.41e-18 12/280 (0.043)
Hepatic Fibrosis/Hepatic Stellate Cell Activation 2.37e-07 5/135 (0.037)
Communication between Innate and Adaptive Immune Cells 5.03e-05 3/90 (0.033)
LXR/RXR Activation 5.51e-05 3/86 (0.035)
Colorectal Cancer Metastasis Signaling 9.92e-05 4/247 (0.016)
doi:10.1371/journal.pone.0079549.t003
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granulocytes and monocytes, suggesting an activated immune
system as compared with the other groups. However, the
difference is small and absolute numbers of immune cells are all
below the threshold.
Partly due to the limited number of patients and the
heterogeneous phenotype in our cohort of patients, we could not
establish an association with clinical characteristics or duration of
disease. Therefore, we are at the moment unable to determine
whether the patient classification may help predict the course of
disease (e.g. exacerbations) in the future. In a one and a half year
follow up of our patients, we did not find an association between
the groups or course of disease such as exacerbation. However,
supervised analysis of those CD patients that encountered an
exacerbation and those with prolonged remission, illustrated
differences in gene expression profiles (Table S5). Interestingly,
one of these genes, interleukin-8, has been extensively associated
with the pathogenesis of CD. [25,31,32] Previously, we have
observed enhanced interleukin-8 production in buccal epithelial
cells of pediatric CD patients, [33] indicating a potential role for
this chemokine in the pathogenesis of pediatric CD. Moreover,
other genes in this analysis, such as protein tyrosine phosphatase,
non-receptor type 2 (PTPN2) and prostaglandin E receptor 4
(PTGER4) have also been associated with active CD. [34,35] A
prospective study that assesses RNA expression longitudinally (at
the time of diagnosis, during remission and at the time of
exacerbation) may provide answers whether the expression of
these and/or other genes can predict disease exacerbation.
In summary, we find that remission in pediatric IBD patients is
associated with gene expression profiles that are distinct from
healthy persons. We conclude that in the absence of clinical
symptoms, various immune-related pathways are still active,
suggesting subclinical immunological activation.
Our studies suggest that monitoring of specific gene expression
profiles may help identify subclasses of pediatric IBD patients and
may deliver novel sets of genes associated with different IBD types
and stages. Prospective clinical studies using both clinical disease
activity markers as well as ‘‘immunological disease activity’’ using
bioinformatics may lead to new perspectives in treatment regimes
of IBD patients.
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